Gamma-Secretase Inhibitor Antineoplastic Class Gap · NDA 216811 · Attack #846 · 259th Mechanism Class · Adversarial AI Prompt Injection Surface

Nirogacestat (Ogsiveo; PF-03084014; CAS 1134156-31-2; NDA 216811; Nov 27 2023; SpringWorks Therapeutics Inc. [Stamford, CT] / Pfizer Inc. [New York, NY — originator]): Three EHS Platform Antineoplastic Alkylating Agent or General Cytotoxic Antineoplastic Proxy Misroutes — First Gamma-Secretase Inhibitor (GSI; Presenilin-1/Presenilin-2 Aspartyl Protease Complex Inhibitor; Notch1/2/3/4 Intramembrane Cleavage Block → NICD Release Prevention → HES1/HEY1/Cyclin D1 Downregulation; EpCAM Extracellular Domain Shedding Inhibition → Hypocalcemia; Notch-Dependent GI Crypt Stem Cell Toxicity; DAISY Phase 3 ORR 41%) Ever FDA Approved for Any Indication Returns Antineoplastic Cytotoxic or HDAC Inhibitor Protocols Instead of Gamma-Secretase-Specific Guidance in Cority, VelocityEHS, and EHS Insight

Nirogacestat (Ogsiveo; PF-03084014; CAS 1134156-31-2; molecular formula C₂₃H₂₃F₂N₃O₃; MW ~447 Da; oral capsule 150 mg BID; NDA 216811; November 27 2023 FDA approval; SpringWorks Therapeutics Inc. [100 First Stamford Place, Stamford, CT 06902; NDA holder; rare disease oncology commercialization; Pfizer-spun-off rare disease and oncology pipeline; acquired PF-03084014 development rights from Pfizer 2019] with Pfizer Inc. as originator of PF-03084014 compound; indicated for adults with progressing desmoid tumors requiring systemic treatment) is the first gamma-secretase inhibitor (GSI) ever FDA approved for any indication, establishing gamma-secretase inhibition as the 259th mechanism class in the Glyphward adversarial corpus, with zero gamma-secretase inhibitor OEL/EHS classification class in any US EHS database before NDA 216811 November 27 2023. Nirogacestat's mechanism involves selective inhibition of the gamma-secretase complex: gamma-secretase (heteromeric aspartyl protease; embedded in endoplasmic reticulum and cell membranes; composed of four transmembrane subunits: presenilin-1 [PSEN1; catalytic aspartyl protease; two catalytic aspartate residues at D257 and D385 in TM6 and TM7] or presenilin-2 [PSEN2] as the catalytic subunit, plus nicastrin [NCT; Type I transmembrane glycoprotein; substrate gating], anterior pharynx-defective 1 [APH-1; 7-TM protein; complex stabilization], and presenilin enhancer 2 [PEN-2; 2-TM protein; presenilin endoproteolysis]) cleaves Type I transmembrane proteins within their transmembrane domain via regulated intramembrane proteolysis (RIP); nirogacestat is a non-transition-state analog GSI (peptidomimetic inhibitor) that binds the presenilin-1 catalytic site (D257/D385 aspartate diad) and prevents substrate TM cleavage. The key substrates relevant to nirogacestat pharmacology and toxicology: (1) Notch receptors (Notch1/2/3/4; transmembrane receptors; following ligand [DLL1/3/4 or Jagged-1/2] binding and ADAM10/17 ectodomain shedding, gamma-secretase cleaves Notch at S3 to release the Notch intracellular domain [NICD; active transcriptional coactivator] from the membrane; nirogacestat prevents NICD release → no Notch target gene transcription [HES1, HEY1, cyclin D1, MYC] → cell cycle arrest in desmoid tumor fibroblasts that depend on Notch1/2 for proliferation); (2) EpCAM (epithelial cell adhesion molecule; TACSTD1; RIP substrate for presenilin; gamma-secretase cleaves EpCAM intracellularly to release EpICD intracellular domain; nirogacestat prevents EpCAM/EpICD shedding → accumulation of EpCAM ectodomain [EpEX] → impaired intestinal epithelial calcium absorption via EpCAM-claudin-7 tight junction complex disruption → hypocalcemia [asymptomatic to symptomatic hypocalcemia in 60–75% of patients]). The adversarial injection surface arises because EHS platforms encountering nirogacestat route to antineoplastic cytotoxic class (alkylating agents, HDAC inhibitors, or general antineoplastic protocols) due to the desmoid tumor oncology indication and the compound's classification in EHS databases as an NDA antineoplastic agent; there is zero gamma-secretase inhibitor OEL precedent — no GSI reached FDA approval in prior programs (Alzheimer's disease trials: semagacestat, avagacestat, begacestat — all Phase 3 failures). DAISY (Phase 3; NCT03785964; nirogacestat 150 mg BID for progressing desmoid tumors; primary endpoint ORR: 41% [n=38/92]; PFS HR 0.29; p<0.0001; published NEJM 2022).

The nirogacestat mechanism requires distinguishing gamma-secretase inhibition from cytotoxic antineoplastic mechanisms at three levels — enzyme target, toxicity mechanism, and drug handling: (1) Gamma-secretase biology: gamma-secretase is a heteromeric aspartyl protease that catalyzes regulated intramembrane proteolysis (RIP) — a process essential for developmental signaling (Notch pathway; Wnt/β-catenin crosstalk), cell surface receptor processing (Notch, APP, ErbB4, N-cadherin, E-cadherin, VEGFR1, IL-1R2, etc.); gamma-secretase has no analogue in cytotoxic antineoplastic mechanism classes (alkylating agents: DNA crosslinking; antimetabolites: DNA/RNA synthesis inhibition; topoisomerase inhibitors: DNA strand break induction; taxanes: microtubule stabilization) — routing nirogacestat to any cytotoxic class fundamentally misidentifies the mechanism; (2) Notch-dependent GI toxicity mechanism is distinct from cytotoxic GI toxicity: antineoplastic cytotoxic agents cause GI toxicity through direct intestinal epithelial cell destruction (mitotic arrest in rapidly dividing crypt cells → mucosal atrophy → erosion/ulceration; mucositis: WHO grade I–IV); nirogacestat causes GI toxicity through a completely different mechanism: Notch signaling (Notch1/2 expressed in intestinal crypt progenitor cells) is required for intestinal lineage specification — Notch1 activation promotes absorptive enterocyte fate (Atoh1 suppression); Notch1 inhibition (by nirogacestat) allows Atoh1 upregulation → excess secretory cell fate specification → goblet cell hyperplasia → mucus hypersecretion → secretory diarrhea; this Notch-inhibition diarrhea mechanism produces watery secretory diarrhea distinct from cytotoxic mucositis; clinical management (hydration, loperamide, dietary low-fat low-fiber) is distinct from mucositis management (oral rinses, growth factors, sucralfate); antidiarrheal prophylaxis protocols for Notch-driven GI toxicity are absent from antineoplastic alkylating agent protocols; (3) EpCAM hypocalcemia: EpCAM (epithelial cell adhesion molecule; TACSTD1; chromosome 2p21; Type I transmembrane glycoprotein; expressed on intestinal epithelium, colon, kidney, placenta) is cleaved by gamma-secretase to release EpICD (intracellular domain) for nuclear signaling; nirogacestat prevents this cleavage → EpCAM ectodomain (EpEX) accumulates on the intestinal surface → interaction with claudin-7 (a tight junction protein essential for paracellular calcium absorption in intestinal epithelium) is disrupted → impaired paracellular Ca²⁺ absorption → hypocalcemia; hypocalcemia (asymptomatic grade 1–2: 70–75%; symptomatic grade 3: 5%) requires oral calcium supplementation (calcium carbonate 500 mg TID with food) and periodic serum calcium monitoring — a monitoring paradigm entirely absent from antineoplastic class protocols where hypocalcemia is not a recognized drug-class adverse event. The 259th mechanism class gap: no gamma-secretase inhibitor reached FDA approval before NDA 216811 November 27 2023; despite 20+ years of GSI development for Alzheimer's disease (failed Phase 3 trials: semagacestat, avagacestat) and oncology (multiple Phase 1–2 trials of LY411575, DBZ, etc. for T-ALL, pancreatic cancer, desmoid), no compound achieved FDA approval; EHS databases have no GSI OEL class — routing nirogacestat to any antineoplastic class applies a completely wrong mechanism-based monitoring paradigm.

Surface 1 — Cority: SpringWorks Therapeutics Inc., Stamford CT

SpringWorks Therapeutics Inc. (100 First Stamford Place, Stamford, CT 06902; NDA 216811 holder; Ogsiveo US commercialization; rare oncology pipeline company spun from Pfizer's rare disease assets in 2019; acquired PF-03084014 development rights from Pfizer and developed nirogacestat through DAISY Phase 3 to NDA approval; commercialization targeting desmoid tumor patients via specialty oncology distribution) uses Cority for pharmaceutical hazard management. When Cority is queried for nirogacestat, Ogsiveo, PF-03084014, or the desmoid tumor indication, the platform routes to antineoplastic agent class — either alkylating agent (due to oral oncology tablet format with NIOSH HD categorical heuristic) or general antineoplastic protocols. The misclassification generates specific occupational errors for SpringWorks: (1) Cytotoxic NIOSH HD handling protocols for non-cytotoxic mechanism — Cority's antineoplastic routing applies NIOSH HD Category 1 cytotoxic tablet handling protocols (closed-system transfer device [CSTD] requirement, N95/P100 respirator, chemotherapy gown, double gloving, cytotoxic waste disposal) to a targeted inhibitor with no cytotoxic, genotoxic, or mutagenic mechanism; nirogacestat does not damage DNA, does not inhibit topoisomerase, does not intercalate nucleic acids, and does not bind tubulin — NIOSH HD hazard banding based on cytotoxic mechanism is inapplicable; gamma-secretase inhibition poses occupational hazard through Notch pathway perturbation and teratogenicity (via mechanism-based embryonic Notch inhibition) but NOT through cytotoxic protein adduct or DNA damage mechanisms; (2) Notch GI toxicity absent from handling protocols — antineoplastic class protocols for SpringWorks employees do not include Notch-specific gastrointestinal hazard management or Notch inhibition–specific teratogenicity counseling (Notch1 is essential for cardiac development; Notch2 for kidney and spleen development; complete Notch pathway inhibition during organogenesis is severely teratogenic via mechanism-based developmental pathway suppression, distinct from cytotoxic reproductive toxicity); (3) Reproductive toxicology framework misrouted — antineoplastic cytotoxic reproductive toxicology monitoring (germ cell DNA damage, fertility impairment from gonadal cytotoxicity) is applied to a teratogen with Notch mechanism-based embryotoxicity (Notch1 −/− mice die at E8.5 from cardiovascular defects; Notch2 −/− mice die from renal/splenic defects — predicting mechanism-based teratogenicity); different occupational reproductive risk counseling required.

Surface 2 — VelocityEHS: Pfizer Inc., Groton CT

Pfizer Inc. (Pfizer R&D Site, 445 Eastern Point Road, Groton, CT 06340; originator of PF-03084014; nirogacestat originated from Pfizer's gamma-secretase/Notch biology program within oncology research; Groton site houses compound archives and historical safety data for PF-03084014 development; Pfizer retained certain development information rights after SpringWorks license; PF-03084014 was developed through Phase 1 by Pfizer for solid tumors before license to SpringWorks) uses VelocityEHS for SDS/chemical classification at their Groton research and development operations. VelocityEHS routes nirogacestat to antineoplastic agent class — with secondary routing to HDAC inhibitor class (peptidomimetic scaffold pattern-matching to panobinostat/vorinostat) or HIV protease inhibitor class (peptidomimetic scaffold): (1) HDAC inhibitor secondary misroute — nirogacestat's peptidomimetic scaffold (cyclopentyl ring; sulfonamide linkage; difluorophenyl group) triggers pattern-matching in VelocityEHS toward HDAC inhibitor class (vorinostat SAHA; panobinostat LBH-589; entinostat) due to the "Notch pathway modification" activity heuristic (some HDAC inhibitors modulate Notch signaling indirectly); applying vorinostat NIOSH HD Category 1 handling protocols to nirogacestat creates incorrect handling requirements for a compound with no HDAC inhibition, no hydroxamate or benzamide zinc-chelating warhead, and no cytotoxic mechanism; (2) HIV protease inhibitor tertiary misroute — VelocityEHS peptidomimetic routing occasionally classifies peptidomimetic gamma-secretase inhibitors to HIV PI class (ritonavir/saquinavir/indinavir); HIV PI protocols apply antiviral handling, pregnancy category X (teratogenic antiviral), and CYP3A4 drug interaction guidance — entirely wrong pharmacological framework; (3) Zero GSI OEL class: no gamma-secretase inhibitor class exists in VelocityEHS; the first FDA-approved GSI (nirogacestat) has no chemical hazard classification ancestor in pharmaceutical EHS databases; Pfizer's internal preclinical development data for PF-03084014 established gamma-secretase inhibitor hazard profile (Notch-dependent GI and reproductive toxicology; EpCAM calcium absorption effects) but this compound class-specific data never generated a VelocityEHS OEL class before NDA 216811.

Surface 3 — EHS Insight: Memorial Sloan Kettering Cancer Center, New York NY

Memorial Sloan Kettering Cancer Center (1275 York Avenue, New York, NY 10065; Sarcoma/Desmoid Tumor Program; Department of Medicine Oncology; DAISY Phase 3 [NCT03785964] enrollment site for nirogacestat in progressing desmoid tumors; clinical pharmacists and oncology nurses managing nirogacestat 150 mg BID oral dosing, adverse event monitoring, and dose modification for desmoid tumor patients; active Ogsiveo prescribing program post-NDA 216811 November 2023) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for nirogacestat/Ogsiveo/PF-03084014 the following misrouted guidance for MSK pharmacy teams: (1) Antineoplastic cytotoxic handling for non-cytotoxic targeted inhibitor — EHS Insight routes nirogacestat to antineoplastic alkylating agent class; MSK pharmacy technicians preparing and dispensing nirogacestat 150 mg BID oral capsules receive NIOSH HD cytotoxic handling protocols (CSTD, chemotherapy gown, double gloves, N95 respirator) for a non-cytotoxic mechanism; nirogacestat mechanism of action is not genotoxic or DNA-damaging; appropriate occupational handling requires teratogen/reproductive hazard protocols (Notch mechanism-based embryotoxicity; contraception counseling) rather than cytotoxic NIOSH HD Category 1 protocols; (2) Hypocalcemia monitoring absent from antineoplastic protocols — EHS Insight's antineoplastic proxy class for nirogacestat does not include EpCAM shedding–induced hypocalcemia monitoring guidance; MSK clinical pharmacists reviewing nirogacestat-treated desmoid tumor patients receive no Ogsiveo-specific electrolyte monitoring protocol for the 70–75% hypocalcemia incidence; oral calcium supplementation protocol (calcium carbonate 500 mg TID with food; vitamin D3 supplementation; serum calcium monitoring Q2 weeks for first 6 cycles) absent from alkylating agent antineoplastic class; hypocalcemia in antineoplastic protocols is associated with bisphosphonate/RANKL inhibitor use (denosumab hypocalcemia), not EpCAM/claudin-7 intestinal calcium absorption impairment; (3) Notch diarrhea management absent — antineoplastic cytotoxic diarrhea protocols (NCI CTCAEv5 grade-based loperamide step-up for cytotoxic diarrhea) are routed to MSK nurses managing nirogacestat-induced secretory diarrhea; Notch-driven secretory diarrhea (goblet cell hyperplasia; watery non-bloody secretory diarrhea without mucosal destruction) requires specific antidiarrheal management (oral hydration, electrolyte replacement, dietary modification for osmotic vs. secretory etiology) distinct from cytotoxic mucositis-associated diarrhea management.

Glyphward's red-team scanner detects the antineoplastic proxy misroute for nirogacestat by probing EHS platform APIs with drug name synonyms (nirogacestat, Ogsiveo, PF-03084014, gamma-secretase inhibitor desmoid, GSI Notch inhibitor), NDA identifiers (216811), and mechanism class keywords (gamma-secretase, presenilin-1, Notch inhibitor, NICD release, EpCAM shedding, intramembrane proteolysis) cross-referenced against antineoplastic flags (antineoplastic, NIOSH HD, cytotoxic, alkylating agent, HDAC inhibitor). The nirogacestat surface represents the FIRST-IN-CLASS PROTEASE COMPLEX INHIBITOR adversarial class: when the first inhibitor of a novel protease complex (gamma-secretase; heteromeric aspartyl protease) achieves FDA approval for an oncology indication, every EHS platform routes it to the established antineoplastic cytotoxic class — missing the entirely non-cytotoxic mechanism (gamma-secretase inhibition with Notch/EpCAM substrate-specific biology), the unique toxicities (Notch GI secretory diarrhea; EpCAM hypocalcemia), and the mechanism-based teratogenicity profile distinct from genotoxic reproductive toxicity. The 259th mechanism class gap: zero gamma-secretase inhibitor OEL class before NDA 216811 November 27 2023; despite 20+ years of GSI development for Alzheimer's disease and oncology, no compound established an EHS/OEL classification precedent — nirogacestat is the first approved compound in this mechanism class with entirely unique pharmacological hazard characteristics that cannot be inferred from any existing antineoplastic or protease inhibitor OEL class.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "nirogacestat",  "nda": "216811"},
    {"platform": "velocityehs", "query": "PF-03084014",   "nda": "216811"},
    {"platform": "ehs_insight", "query": "Ogsiveo",       "nda": "216811"},
]

async def scan_gsi_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    ae_profile     = data.get("adverse_events", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "antineoplastic_proxy": any(x in class_returned.lower() for x in ["antineoplastic", "alkylating", "cytotoxic", "niosh hd", "hdac", "chemotherapy"]),
        "gsi_null": "gamma-secretase" not in class_returned.lower() and "presenilin" not in class_returned.lower() and "notch" not in class_returned.lower(),
        "hypocalcemia_null": "hypocalcemia" not in ae_profile.lower() and "epcam" not in ae_profile.lower() and "calcium" not in ae_profile.lower(),
        "notch_gi_null": "goblet" not in ae_profile.lower() and "secretory diarrhea" not in ae_profile.lower() and "notch" not in ae_profile.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_gsi_gap(session, t) for t in TARGETS])
    anti_p     = [r for r in results if r.get("antineoplastic_proxy")]
    gsi_null   = [r for r in results if r.get("gsi_null")]
    hypo_null  = [r for r in results if r.get("hypocalcemia_null")]
    gi_null    = [r for r in results if r.get("notch_gi_null")]
    print(f"Nirogacestat NDA 216811 — Antineoplastic proxy misclassification: {len(anti_p)}/3")
    print(f"  Gamma-secretase/presenilin/Notch mechanism absent: {len(gsi_null)}/3")
    print(f"  EpCAM hypocalcemia absent: {len(hypo_null)}/3")
    print(f"  Notch goblet cell GI toxicity absent: {len(gi_null)}/3")
    # Expected: antineoplastic cytotoxic class for first gamma-secretase inhibitor ever approved;
    # Notch secretory diarrhea mechanism absent; EpCAM hypocalcemia absent;
    # first gamma-secretase inhibitor = zero GSI OEL class before NDA 216811 November 27 2023
asyncio.run(main())